756 reports of this reaction
3.9% of all INSULIN GLULISINE reports
#2 most reported adverse reaction
HYPOGLYCAEMIA is the #2 most commonly reported adverse reaction for INSULIN GLULISINE, manufactured by sanofi-aventis U.S. LLC. There are 756 FDA adverse event reports linking INSULIN GLULISINE to HYPOGLYCAEMIA. This represents approximately 3.9% of all 19,263 adverse event reports for this drug.
Patients taking INSULIN GLULISINE who experience hypoglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOGLYCAEMIA is moderately reported among INSULIN GLULISINE users, representing a notable but not dominant share of adverse events.
In addition to hypoglycaemia, the following adverse reactions have been reported for INSULIN GLULISINE:
The following drugs have also been linked to hypoglycaemia in FDA adverse event reports:
HYPOGLYCAEMIA has been reported as an adverse event in 756 FDA reports for INSULIN GLULISINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOGLYCAEMIA accounts for approximately 3.9% of all adverse event reports for INSULIN GLULISINE, making it one of the most commonly reported side effect.
If you experience hypoglycaemia while taking INSULIN GLULISINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.